Hyperfine Reports 44.8% Revenue Growth to $3.9 Million in Q2 2026

Hyperfine, Inc. reported significant financial results for the second quarter of 2026, with total revenues reaching $3.9 million, a 44.8% increase compared to $2.7 million in the same period of 2025. For the first half of 2026, revenues totaled $7.8 million, up 61.5% from $4.8 million in the prior year. The growth was primarily driven by increased sales of the Swoop® Portable MR Imaging® System, which saw unit sales rise from 8 to 12 in the second quarter and from 14 to 22 in the first half year-over-year. Despite the revenue growth, the company reported a net loss of $9.3 million for the quarter, slightly higher than the $9.2 million loss in the same quarter of 2025, and a total net loss of $17.9 million for the first half of 2026, down from $18.6 million in the previous year.

Operationally, Hyperfine has made strides in expanding its market presence and product offerings. The company launched its next-generation Swoop® system powered by Optive AI™ software in mid-2025, which has contributed to increased adoption rates. The company has also received multiple regulatory approvals, including the latest CE Mark and UKCA Mark for its next-generation system in March 2026, allowing for broader commercialization in Europe. As of June 30, 2026, Hyperfine had cash and cash equivalents of $43.5 million, bolstered by financing activities that included $25.3 million raised through a combination of debt and equity offerings during the first half of the year.

In terms of expenses, Hyperfine's total operating expenses decreased by 4.3% to $10.4 million in the second quarter of 2026, compared to $10.9 million in the same period of 2025. Research and development expenses fell by 14.9% to $3.9 million, reflecting a reduction in headcount and increased grant fulfillment credits. General and administrative expenses remained relatively stable, while sales and marketing expenses increased by 6.1% as the company invested in growth initiatives. The company’s interest expense rose significantly due to a new loan agreement, which contributed to the overall net loss.

Looking ahead, Hyperfine remains focused on expanding its commercialization efforts both domestically and internationally. The company aims to leverage its recent regulatory approvals to penetrate new markets and enhance its product offerings. Management anticipates that continued investment in research and development, along with strategic partnerships, will drive future growth. However, the company acknowledges the risks associated with market conditions and the need for additional financing to support its operations and growth initiatives. Hyperfine's management believes that its current cash position, combined with anticipated revenue growth, will sustain operations for at least the next twelve months.